Establishing a mass spectrometry-based system for rapid detection of SARS-CoV-2 in large clinical sample cohorts.

Autor:	Cardozo KHM; Division of Research and Development, Fleury Group, 04344-070, São Paulo, SP, Brazil., Lebkuchen A; Division of Research and Development, Fleury Group, 04344-070, São Paulo, SP, Brazil., Okai GG; Division of Research and Development, Fleury Group, 04344-070, São Paulo, SP, Brazil., Schuch RA; Division of Research and Development, Fleury Group, 04344-070, São Paulo, SP, Brazil., Viana LG; Division of Research and Development, Fleury Group, 04344-070, São Paulo, SP, Brazil., Olive AN; Division of Research and Development, Fleury Group, 04344-070, São Paulo, SP, Brazil., Lazari CDS; Division of Infectious Diseases, Fleury Group, 04344-070, São Paulo, SP, Brazil., Fraga AM; Division of Research and Development, Fleury Group, 04344-070, São Paulo, SP, Brazil., Granato CFH; Division of Infectious Diseases, Fleury Group, 04344-070, São Paulo, SP, Brazil., Pintão MCT; Division of Research and Development, Fleury Group, 04344-070, São Paulo, SP, Brazil., Carvalho VM; Division of Research and Development, Fleury Group, 04344-070, São Paulo, SP, Brazil. valdemir.carvalho@grupofleury.com.br.
Jazyk:	angličtina
Zdroj:	Nature communications [Nat Commun] 2020 Dec 03; Vol. 11 (1), pp. 6201. Date of Electronic Publication: 2020 Dec 03.
DOI:	10.1038/s41467-020-19925-0
Abstrakt:	The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is pressing public health systems around the world, and large population testing is a key step to control this pandemic disease. Here, we develop a high-throughput targeted proteomics assay to detect SARS-CoV-2 nucleoprotein peptides directly from nasopharyngeal and oropharyngeal swabs. A modified magnetic particle-based proteomics approach implemented on a robotic liquid handler enables fully automated preparation of 96 samples within 4 hours. A TFC-MS system allows multiplexed analysis of 4 samples within 10 min, enabling the processing of more than 500 samples per day. We validate this method qualitatively (Tier 3) and quantitatively (Tier 1) using 985 specimens previously analyzed by real-time RT-PCR, and detect up to 84% of the positive cases with up to 97% specificity. The presented strategy has high sample stability and should be considered as an option for SARS-CoV-2 testing in large populations.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu